Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer

ABT‐751 is an orally bioavailable sulfonamide with antimitotic properties. A nonrandomized phase 1 dose‐escalation study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose‐limiting toxicity (DLT), and pharmacok...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Main Authors: Rudek, Michelle A., Dasari, Arvind, Laheru, Daniel, He, Ping, Jin, Runyan, Walker, Rosalind, Taylor, Gretchen E., Jimeno, Antonio, Donehower, Ross C., Hidalgo, Manuel, Messersmith, Wells A., Purcell, W. Thomas
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2016
Assuntos:
Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4892995/
https://ncbi.nlm.nih.gov/pubmed/26632033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.681
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares